fashion -WSS

fashion

author：fashion 2025-09-06 08:39:41 - browse：78429

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Change Healthcare cyberattack prompts Medicare loan program

leisure time

WSS

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

AstraZeneca loses challenge to Medicare drug price negotiation

Why getting cancer drugs just got harder for rural patients

International team creates first chimeric human

ALS groups 'won't be played again' by the FDA, drug sponsors

Just how do doctors, lawmakers, and the public define abortion?

entertainment

fashion

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Drug repurposing or repositioning? The language matters

International team creates first chimeric human

Psychedelics group wrestles with new pharma identity

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Activists slam private health insurers over coverage restrictions

RSV vaccines may be linked to small increased risk of developing GBS

Duchenne breakthrough therapy leaves behind pioneering families

Kenai launches with $82 million for Parkinson’s stem cell therapy

hotspot

AstraZeneca loses challenge to Medicare drug price negotiation

ALS groups 'won't be played again' by the FDA, drug sponsors

AstraZeneca loses challenge to Medicare drug price negotiation

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

How to fix the rural physician shortage in the U.S.

Change Healthcare cyberattack outage could last weeks

focus

leisure time

explore

entertainment